GUANGDONG INV
00270
HKBN
01310
KB LAMINATES
01888
BOC HONG KONG
02388
POWER ASSETS
00006
HK Stock MarketDetailed Quotes
00874 BAIYUNSHAN PH
- 18.200
- -0.120-0.66%
Market Closed Dec 10 16:08 CST
29.59BMarket Cap7.79P/E (TTM)
18.720High18.100Low2.48MVolume18.660Open18.320Pre Close45.64MTurnover1.13%Turnover Ratio6.61P/E (Static)1.63BShares23.55852wk High0.74P/B4.00BFloat Cap16.17852wk Low1.27Dividend TTM219.90MShs Float37.435Historical High0.823Dividend LFY3.38%Amplitude-6.783Historical Low18.388Avg Price2000Lot Size6.95%Div YieldTTM4.52%Div Yield LFY
BAIYUNSHAN PH News
Baiyunshan (00874.HK) saw a shareholding reduction of 0.348 million shares by Norges Bank.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on November 27, 2024, baiyunshan ph (00874.HK) was sold by Norges Bank on the exchange at an average price of HKD 18.0525 per share, selling 0.348 million shares, involving approximately 6.2823 million Hong Kong dollars. After the shareholding, Norges Bank's latest number of shares held is 10.855 million shares, and the shareholding ratio has decreased from 5.09% to 4.94%.
Baiyunshan (00874.HK)'s subsidiary Guangzhou Medicine sells the first new underlying assets to Xingzheng Asset Management and receives a purchase price of 0.524 billion yuan.
Gelonghui reported on November 28 that baiyunshan ph (00874.HK) announced that on November 28, 2024, the company's non-wholly-owned subsidiary Guangzhou Medicine signed a "New Basic Asset Delivery Confirmation Letter" with Xingzheng Asset Management according to the Basic Asset Sale Agreement (Phase IV), confirming the sale of the first newly added basic asset to Xingzheng Asset Management and receiving a purchase price of 524,000,713.50 yuan.
Baiyunshan Pharma's Unit Gets Nod to Make Changes to Selaginella Jiangnanensis Tablets
Baiyunshan Pharma Gets Nod to Market Anti-Tumor Drug
Baiyunshan (600332.SH): Cefdinir granules have received a pharmaceutical registration certificate.
On November 25, Gelonghui reported that baiyunshan ph (600332.SH) announced that its holding subsidiary, Guangzhou baiyunshan ph Tianxin Pharmaceutical Co., Ltd. (referred to as 'Tianxin Pharmaceutical'), received the pharmaceutical registration certificate approved and issued by the National Medical Products Administration for Cefdinir Granules (50mg). Cefdinir Granules belong to the third generation of cephalosporin antibiotics, which mainly exert their bactericidal effect by inhibiting the synthesis of bacterial cell walls, making it a broad-spectrum antibiotic that was approved for market launch in 2002 in china. It is suitable for the treatment of Staphylococcus, Streptococcus, Pneumococcus, Streptococcus dysgalactiae, and Propionibacterium that are sensitive to Cefdinir.
Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt Responsibly
China Approves Baiyunshan Pharma Unit's Supplementary Application for Traditional Chinese Drug
Baiyunshan (600332.SH): The subsidiary has received approval for the supplementary pharmaceutical application.
On November 21, Gelonghui reported that baiyunshan ph (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. (referred to as "Zhongyi Pharmaceutical"), received the "Notification of Approval for Supplementary Application of Pharmaceutical" issued by the National Medical Products Administration. Zhongyi Pharmaceutical submitted this pharmaceutical supplementary application to the National Medical Products Administration on October 22, 2024, and it was accepted on October 25, 2024. The compound cold remedy capsule is used for the symptoms of wind-heat cold, including fever, slight aversion to cold, body aches, dry mouth and thirst, nasal congestion with thick mucus, red and swollen throat, cough, and yellow thick phlegm. This pharmaceutical was originally produced by the company's subsidiary Guangzhou Baiyunshan Qixing.
The baiyunshan ph (600332.SH) subsidiary He J Gong Pharmaceutical Factory has obtained approval for the new production line and production scope.
baiyunshan ph (600332.SH) issued a notice that the company's subsidiary Guangzhou baiyunshan ph Pharmaceutical Group Co., Ltd. baiyun...
Baiyunshan (00874.HK) has had a shareholding reduction of 0.664 million shares by Norges Bank.
On November 20, Gelonghui reported that according to the latest equity disclosure information from the Stock Exchange, on November 14, 2024, baiyunshan ph (00874.HK) was reduced by Norges Bank in the market by 664,000 shares at an average price of 18.312 Hong Kong dollars per share, involving about 12.1592 million Hong Kong dollars. After the shareholding reduction, the latest number of shares held by Norges Bank is 14.935 million shares, and the shareholding ratio has decreased from 7.09% to 6.79%.
Guangzhou Baiyunshan Pharmaceutical Unit Gets Additions to Drug Production License
With declining performance and senior executives falling from power, why can't baiyunshan (00874) rise up relying on domestic "Viagra"?
Whether it is the early involvement in the "network removal" incident, where certain pharmaceutical products in provinces like shanxi, anhui, guizhou, shandong were stripped of their online procurement qualifications; or the failure of its subsidiary Guangzhou Pharmaceuticals' IPO, or the turmoil in senior management and decline in performance since 2024, all indicate that baiyunshan ph's development may not be smooth.
Baiyunshan (00874.HK) subsidiary pharmaceutical production license change.
November 18th, Baiyunshan (00874.HK) announced that recently, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company")'s wholly-owned subsidiary Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. (hereinafter referred to as "Mingxing Pharmaceutical") received the "Pharmaceutical Production License" approved and issued by the Guangdong Provincial Pharmaceutical Supervision Administration, agreeing to add new production workshops, production lines, and production scopes for Mingxing Pharmaceutical, and passing the compliance inspection of pharmaceutical production quality management standards. Agreed that Mingxing Pharmaceutical is located at "99 Jianxu San Road, Baiyun District, Guangzhou City", with new production workshops "Manufacturing Department Six, Manufacturing Department Eight", and new
Hong Kong's Department of Health: To develop Hong Kong into a gateway for the internationalization of traditional Chinese medicine and Chinese herbal medicine.
Secretary for Food and Health of the Hong Kong Special Administrative Region, Dr. Constance Chan, stated that in order to promote the standardization and internationalization of traditional chinese medicine, Hong Kong aims to become a gateway for the internationalization of traditional chinese medicine.
Baiyunshan (00874.HK) was subjected to shareholding of 0.808 million shares by Norges Bank.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on November 7th, 2024, baiyunshan ph (00874.HK) was shareholding by Norges Bank at an average price of HK$18.3615 per share on November 1, 2024, reducing 0.808 million shares, involving approximately HK$14.8361 million. After the shareholding, Norges Bank's latest number of shares held is 19.757 million shares, and the shareholding ratio decreased from 9.35% to 8.98%.
Baiyunshan Pharmaceutical (00874.HK) obtained a supplement application approval for pharmaceuticals at its branch.
Galunhui November 6th | Baiyunshan (00874.HK) announced that recently, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as 'the Company')- Baiyunshan Pharmaceutical Factory of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as 'Baiyunshan Pharmaceutical Factory') received the 'Drug Supplementary Application Approval Notice' issued by the National Medical Products Administration (referred to as 'NMPA'). Baiyunshan Pharmaceutical Factory obtained the Drug Supplementary Application Approval Notice for Citric Acid Sildenafil Tablets this time, enriching the variety of its pharmaceutical products, helping enhance the Company's competitiveness in the pharmaceutical market. Baiyunshan Pharmaceutical
Guangzhou Baiyunshan Pharmaceutical's Factory Passes Generic Drug Consistency Evaluation for Two Antibiotics
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Weak Earnings May Only Reveal A Part Of The Whole Picture
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
baiyunshan ph (00874) subsidiary "Pharmaceutical Production License" change
baiyunshan (00874) announced that its subsidiary Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. (hereinafter referred to as...
Trending HK Stocks
HK Dividend Stocks HK Dividend Stocks
Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data. Dividend stocks are stocks of companies in the HK stock market that regularly distribute dividends to shareholders, generally representing stable businesses. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in HK dividend stocks, ranked from highest to lowest based on real-time market data.
